Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether heme oxygenase 1 induction by heme arginate treatment is of influence on adenosine induced vasodilation in healthy individuals.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Radboud University
• Collaborator: Dutch Diabetes Research Foundation

Criteria

Inclusion Criteria:

• at least 18 and no older than 65 on the day of first dosing

• healthy

• Quetelet Index (Body Mass Index) of 18 to 30 kg/m2

• In general, results of haematology and chemistry should be within the laboratory's reference ranges. Determinants of renal and hepatic function should be within twice the upper limit of normal range.

Exclusion Criteria:

• Documented history of sensitivity / idiosyncrasy to medicinal products or excipients

• history of smoking within the past year

• history of or current abuse of drugs, alcohol and/or solvents

• Current use of any (over the counter) medication potentially influencing heme oxygenase or the cardiovascular system

• Inability to understand the nature and extent of the trial and the procedures required

• Participation to a drug trial within 60 days prior to the first dose

• Febrile illness within 3 days before the first dose

• Heterozygosity (LS) or homozygosity (LL) with regard to the number of GT repeats in the HO-1 promoter region